We used quantitative reverse transcription -- polymerase chain reaction (qRT-PCR) to compare the miRNA expression[@R25],[@R26] of CD44^+^ and CD44^−^ PCa cells. The CD44^+^ PCa cell population harbors tumor-initiating and metastatic cells[@R18],[@R19] and is enriched in self-renewal gene *NANOG*[@R27]. CD44^+^ PCa cells were purified from three xenograft models[@R18],[@R19],[@R27],[@R28]: LAPC9, LAPC4, and Du145. For comparison, we also purified LAPC4 CD133^+^ and LAPC9 side population (SP) cells. The CD133^+^ PCa cells are clonogenic in vitro[@R17] and LAPC9 SP is also enriched in tumor-initiating cells[@R28]. We first used unsorted cells to measure the levels of 324 sequence-validated human miRNAs and found that 137 miRNAs were expressed at reliably detectable levels ([Fig. 1a](#F1){ref-type="fig"}). We then compared expression levels of these 137 miRNAs in marker-positive versus marker-negative PCa cell populations and found that miR-34a (1p36.22) was prominently under-expressed in all CD44^+^ populations ([Fig. 1a](#F1){ref-type="fig"}), representing \<3% of the levels in the corresponding CD44^−^ cells ([Fig. 1b](#F1){ref-type="fig"}). The other two miR-34 family members, miR-34b and miR-34c (11q23.1), did not show consistent differences between CD44^+^ and CD44^−^ PCa cells (not shown). Under-expression of miR-34a in CD44^+^ PCa cells was more pronounced than that of let-7b, a tumor suppressive miRNA[@R6] and an important regulator of both normal and cancer stem cells[@R3],[@R4]. miR-34a was also under-expressed in LAPC4 CD133^+^ ([Fig. 1b](#F1){ref-type="fig"}) and LAPC9 SP (not shown) cells. To validate miR-34a under-expression in CD44^+^ PCa cells and to determine the clinical relevance, we purified CD44^+^ and CD44^−^ PCa cells from 18 primary tumors[@R27],[@R29] (HPCa; [Supplementary Table 1](#SD1){ref-type="supplementary-material"}) and compared the miR-34a levels. CD44^+^ HPCa cells expressed miR-34a at levels \~25--70% of those in CD44^−^ cells from the same tumors ([Fig. 1c](#F1){ref-type="fig"}). Altogether, these results suggest that miR-34a is under-expressed in the CD44^+^ PCa cells in both xenograft and primary tumors.

miR-34a is regulated by p53 and induces apoptosis, cell-cycle arrest, or senescence when introduced into cancer cells[@R20]--[@R24],[@R30]. miR-34a levels in ten prostate (cancer) cell types correlated with the p53 status ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}) and transfection of synthetic miR-34a oligonucleotides (oligos), but not the negative control (NC) miRNA oligos, induced cell-cycle arrest, apoptosis or senescence in p53-mutant PCa cells ([Supplementary Data](#SD1){ref-type="supplementary-material"} and [Supplementary Figs. 2 and 3](#SD1){ref-type="supplementary-material"}). To determine whether miR-34a possesses tumor-inhibitory effects, we manipulated miR-34a levels ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}) in a variety of PCa cell types and then implanted the cells subcutaneously (s.c) or orthotopically in the dorsal prostate (DP) in NOD-SCID mice ([Fig. 1d,e](#F1){ref-type="fig"}; [Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). miR-34a transfected LAPC9 ([Fig. 1d](#F1){ref-type="fig"}; [Supplementary Fig. 5a](#SD1){ref-type="supplementary-material"}) and HPCa58 ([Fig. 1e](#F1){ref-type="fig"}) cells produced significantly smaller tumors than the same cells transfected with miR-NC oligos. LAPC9 cells are androgen-dependent whereas HPCa58 cells were from an early-generation xenograft tumor ([Supplementary Methods](#SD1){ref-type="supplementary-material"}). miR-34a also inhibited the secondary transplantation of HPCa58 cells ([Fig. 1e](#F1){ref-type="fig"}). Similar tumor-inhibitory effects of miR-34a were observed with androgen-dependent LAPC4 ([Supplementary Fig. 5b](#SD1){ref-type="supplementary-material"}) and androgen-independent Du145 ([Supplementary Fig. 5d](#SD1){ref-type="supplementary-material"}) and PPC-1 ([Supplementary Fig. 5g](#SD1){ref-type="supplementary-material"}) cells. We also infected PCa cells with lentiviral or retroviral vectors encoding pre-miR-34a ([Supplementary Fig. 1d](#SD1){ref-type="supplementary-material"}) prior to implantation. The viral vector-mediated miR-34a overexpression also inhibited tumor regeneration of LAPC4 ([Supplementary Fig. 5c](#SD1){ref-type="supplementary-material"}), Du145 ([Supplementary Fig. 5e,f](#SD1){ref-type="supplementary-material"}), and LAPC9 (not shown) cells. Histological and immunohistochemical (IHC) examination of tumor sections ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}) revealed increased necrotic areas and reduced Ki-67^+^ cells in miR-34a transfected tumors, which also showed increased expression of HP-1γ, a protein associated with cell-cycle arrest and senescence.

To evaluate whether the miR-34a-mediated tumor inhibition might be due to an effect on the CSC populations, we performed tumor experiments using purified CD44^+^ and CD44^−^ PCa cells. Remarkably, when purified CD44^+^ Du145 cells were infected with lenti-34a, tumor development was completely blocked ([Fig. 1f](#F1){ref-type="fig"}). Similarly, when CD44^+^ LAPC9 cells were transfected with miR-34a oligos ([Fig. 1g](#F1){ref-type="fig"}) or infected with lenti-34a ([Supplementary Fig. 5h](#SD1){ref-type="supplementary-material"}), tumor incidence was virtually abolished. Conversely, introducing an antisense inhibitor of miR-34a (i.e., anti-34a or miR-34a antagomir) into purified CD44^−^ Du145 cells promoted tumor growth ([Fig. 1h](#F1){ref-type="fig"}; [Supplementary Fig. 5i](#SD1){ref-type="supplementary-material"}). Likewise, bulk or CD44^−^ LAPC9 cells transfected with anti-34a oligos generated larger tumors than those with anti-NC oligos ([Fig. 1i](#F1){ref-type="fig"}; [Supplementary Fig. 7a,b](#SD1){ref-type="supplementary-material"}). Importantly, we observed more lung metastasis in the anti-34a transfected group ([Fig. 1j](#F1){ref-type="fig"}; [Supplementary Fig. 7c,d](#SD1){ref-type="supplementary-material"}). Collectively, these results suggest that miR-34a possesses tumor-inhibitory effects in both bulk and purified CD44^+^ PCa cells.

Subsequently, we performed 4 sets of therapeutic experiments ([Fig. 2](#F2){ref-type="fig"}; see [Online Methods](#SD1){ref-type="supplementary-material"}) in NOD-SCID mice bearing pre-established PCa. We first observed that repeated intratumoral injections of miR-34a into PPC-1 tumors halted tumor growth ([Supplementary Fig. 5g](#SD1){ref-type="supplementary-material"}). We then established orthotopic PC3 tumors and, 3 weeks later, injected miR-34a or miR-NC oligos complexed with a lipid-based delivery agent[@R26] into tail veins of mice every two days. Systemically delivered miR-34a reduced PC3 tumor burden by 50% ([Fig. 2a](#F2){ref-type="fig"}). In two therapeutic experiments with orthotopic LAPC9 tumors, miR-34a reduced lung metastasis ([Fig. 2b,e,f](#F2){ref-type="fig"}; [Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}) without affecting tumor growth ([Fig. 2c](#F2){ref-type="fig"}). miR-34a also promoted survival of tumor-bearing animals ([Fig. 2d](#F2){ref-type="fig"}). These results indicate that miR-34a possesses therapeutic efficacy against pre-established prostate tumors.

Since the CD44^+^ PCa cell population is enriched in CSCs, we performed holoclone, colonogenic, and sphere formation assays[@R18],[@R19],[@R27],[@R33],[@R34] to determine whether miR-34a might regulate certain stem cell-associated properties. PCa cell holoclones contain self-renewing cancer cells[@R34] and sphere-formation assays have been widely used to measure stem/progenitor cell activities[@R1],[@R35]. We first established stringent assay conditions in which clones (i.e., holoclones formed in culture dish), colonies (formed in Matrigel or methylcellulose), and (floating) spheres were all of clonal origin ([Supplementary Fig. 9](#SD1){ref-type="supplementary-material"}). Under these conditions, miR-34a overexpression inhibited holoclone formation, clonogenic capacity, and sphere establishment in Du145 ([Fig. 3a,b](#F3){ref-type="fig"}; [Supplementary Fig. 2d,e](#SD1){ref-type="supplementary-material"}), LAPC4 ([Fig. 3c,d](#F3){ref-type="fig"}), and PPC-1 ([Fig. 3e](#F3){ref-type="fig"}; [Supplementary Fig. 3h,i](#SD1){ref-type="supplementary-material"}) cells. Importantly, miR-34a inhibited sphere formation in primary HPCa cells ([Fig. 3f](#F3){ref-type="fig"}; [Supplementary Fig. 10](#SD1){ref-type="supplementary-material"}) and abrogated secondary sphere establishment ([Fig. 3d,f](#F3){ref-type="fig"}). Moreover, HPCa cells infected with lenti-34a formed tiny or differentiated spheres ([Supplementary Fig. 10b](#SD1){ref-type="supplementary-material"}). Of significance, miR-34a overexpression in purified CD44^+^ HPCa116 cells inhibited sphere formation ([Fig. 3g](#F3){ref-type="fig"}) and, by contrast, anti-34a increased the inherently low sphere-forming capacity of CD44^−^ HPCa116 cells by several fold ([Fig. 3h](#F3){ref-type="fig"}). Taken together, these observations indicate that miR-34a negatively regulates stem cell properties of PCa cells.

Cyclin D1, CDK4 and 6, E2F3, N-Myc, c-MET, and BCL-2 have been reported to be direct targets of miR-34a[@R20]--[@R24],[@R26],[@R30]--[@R32]. A survey of some of these molecules revealed that miR-34a affected the levels of cyclin D1, CDK4, CDK6 and c-MET in our PCa models ([Supplementary Fig. 4d,e](#SD1){ref-type="supplementary-material"}; [Supplementary Fig. 6d,e](#SD1){ref-type="supplementary-material"}). Interestingly, we consistently observed a strong inverse correlation between miR-34a levels and CD44 ([Fig. 4a,b](#F4){ref-type="fig"}; [Supplementary Fig. 1a,4e,11a--c](#SD1){ref-type="supplementary-material"}; [Supplementary Table 2](#SD1){ref-type="supplementary-material"}). For example, CD44 protein and CD44^+^ PCa cells were reduced in miR-34a treated tumors ([Fig. 4a](#F4){ref-type="fig"}). Transfected miR-34a downregulated CD44 in PCa cells ([Fig. 4b](#F4){ref-type="fig"}; [Supplementary Fig. 11a,b](#SD1){ref-type="supplementary-material"}). In contrast, CD44 mRNA ([Supplementary Fig. 4e](#SD1){ref-type="supplementary-material"}) and protein ([Supplementary Fig. 11c](#SD1){ref-type="supplementary-material"}) were increased in anti-34a transfected tumors. Of interest, the target-prediction program rna22 (36) revealed 2 putative miR-34a binding sites in the 3'-UTR of CD44 mRNA ([Fig. 4c](#F4){ref-type="fig"}). When we cloned the 3'-UTR fragment harboring both putative miR-34a binding sites downstream of a luciferase coding sequence ([Supplementary Fig. 11d,e](#SD1){ref-type="supplementary-material"}), co-transfection of the luciferase reporter and miR-34a oligos into three PCa cell types produced lower luciferase activity than cells co-transfected with the NC oligos but mutation of the seed sequence in either site, especially the distal site, partially abrogated the suppressive effect of miR-34a ([Fig. 4d](#F4){ref-type="fig"}; [Supplementary Fig. 11f,g](#SD1){ref-type="supplementary-material"}). These results suggest that miR-34a regulates CD44 expression via two binding sites located in the 3'-UTR of the CD44 gene.

To determine whether CD44 represents a *functionally* important target of miR-34a in the context of regulating PCa development, we reduced CD44 expression using a lentiviral CD44-shRNA vector ([Supplementary Fig. 1d](#SD1){ref-type="supplementary-material"}) in LAPC4, PC3, and Du145 cells. CD44 knockdown in LAPC4 cells inhibited both orthotopic tumor regeneration ([Fig. 4e](#F4){ref-type="fig"}) and lung metastasis ([Supplementary Fig. 12](#SD1){ref-type="supplementary-material"}). CD44 knockdown in PC3 cells dramatically inhibited metastasis ([Fig. 4f,g](#F4){ref-type="fig"}; [Supplementary Fig. 13](#SD1){ref-type="supplementary-material"}) without affecting tumor regeneration (not shown). CD44 knockdown in Du145 cells inhibited tumor development in both s.c and orthotopic sites ([Supplementary Fig. 14a,b](#SD1){ref-type="supplementary-material"}) as well as metastasis (not shown). These results not only reveal a critical role of CD44 itself in determining the tumorigenic and metastatic capacity of PCa cells but also indicate that CD44 knockdown phenocopies the anti-PCa effects of miR-34a. Mechanistically, we observed that the CD44^+^ PCa cells demonstrated higher migratory ([Supplementary Fig. 14c,d](#SD1){ref-type="supplementary-material"}) and invasive ([Supplementary Fig. 14e](#SD1){ref-type="supplementary-material"}) capacities than CD44^−^ cells, which were partially inhibited by miR-34a ([Fig. 4h](#F4){ref-type="fig"}; [Supplementary Fig. 14f,g](#SD1){ref-type="supplementary-material"}). 'Rescue' experiments wherein CD44 was overexpressed using a cDNA that lacked the 3'-UTR containing the miR-34a binding sites abrogated miR-34a-mediated inhibition of invasion of CD44^+^ Du145 cells ([Fig. 4i](#F4){ref-type="fig"}), reinforcing CD44 as a direct and *functional* target of miR-34a. In contrast, CD44 overexpression did not significantly relieve miR-34a inhibition of PCa cell proliferation ([Supplementary Fig. 15](#SD1){ref-type="supplementary-material"}).

We report herein underexpression of miR-34a in tumorigenic CD44^+^ PCa cells and demonstrate its potent anti-tumor and anti-metastasis effects. We establish miR-34a as a critical negative regulator of CD44^+^ PCa cells and CD44 itself as an important target of miR-34a. Our results suggest that reduced expression of miR-34a in CD44^+^ PCa cells contributes to PCa development and metastasis by allowing for the elevated expression of CD44 and manifestation of their migratory, invasive and metastatic properties ([Fig. 4j](#F4){ref-type="fig"}). It is interesting that p53, which directly activates miR-34a, also negatively regulates CD44 through a non-canonical p53-binding site in the promoter[@R37], suggesting the importance in controlling CD44 expression. Considering the widespread expression of CD44 in CSCs (7--16) and functional involvement of CD44 in mediating CSC migration and homing[@R38] and in metastasis of many cancers including PCa, the newly identified miR-34a suppression of CD44 reveals a key role for miRNA-based gene regulation. The emerging role of miR-34a in regulating other CSC[@R32],[@R39] properties ([Fig. 4j](#F4){ref-type="fig"}), coupled with the therapeutic effects of miR-34a on lung[@R26] and prostate (this study) tumors, establishes a strong rationale for developing miR-34a as a novel therapeutic targeting tumorigenic PCa cells.
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Methods and any associated references are available in the online version of the paper at <http://www.nature.com/naturemedicine/>.

*Note:* [Supplementary information](#SD1){ref-type="supplementary-material"} *is available on the Nature Medicine website.*
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![Underexpression and tumor-inhibitory effects of miR-34a\
**a**. Experimental scheme. **b**,**c**. Lower miR-34a levels in CD44^+^ xenograft (b; PC4, LAPC4) or primary tumor (HPCa; c) cells. Results are expressed as the mean % of marker-positive over marker-negative cells. **d**,**e**. miR-34a inhibited LAPC9 (d) and HPCa58 (e; black, lenti-ctl; grey, lenti-34a; *n* = 10 and *n* = 7 for 1° and 2° experiments) tumor growth (mean ± S.D). **f**. CD44^+^ Du145 cells infected with lenti-ctl or lenti-34a were injected (10,000 cells each) s.c in NOD-SCID mice. Tumor incidence was 10/10 and mean weight was 0.6 g for lenti-ctl group whereas the incidence for lenti-34a group was 0/10. **g**. Purified CD44^+^ LAPC9 cells were transfected with miR-NC or miR-34a and s.c injected. Tumor incidence was 7/8 and mean weight was 0.5 g for miR-NC group whereas incidence was 1/8 and tumor weight was 0.03 g for miR-34a group (*P* = 0.016, incidence). **h.** Purified CD44^−^ Du145 cells were transfected with anti-NC or anti-34a and s.c injected. Tumor incidence was 5/8 and mean weight was 0.05 g for anti-NC group whereas incidence was 6/8 and tumor weight was 0.2 g for anti-34a group (*P* = 0.038, weight). **i**. Bulk LAPC9 cells were transfected with anti-NC or anti-34a oligos and implanted (100,000 cells) in the DP. Mice were terminated at d 46. Tumor incidences were 5/8 and 7/8 for anti-NC and anti-34a groups, respectively. **j**. Representative microphotographs (animal number and tumor weight indicated on top; scale bar, 100 μm) showing increased lung metastasis by anti-34a (also see [Supplementary Fig. 7c--d](#SD1){ref-type="supplementary-material"}).](nihms255508f1){#F1}

![Therapeutic effects of miR-34a\
**a**. Tail vein-injected miR-34a inhibited orthotopic PC3 tumor growth (*n* = 9 each). **b**--**d**. Tail vein-injected miR-34a oligos inhibited metastasis (GFP^+^ foci in the endpoint lungs; mean ± S.D, *n* = 6/group) of orthotopic LAPC9-GFP tumors (b) without significantly affecting tumor growth (c) and extended animal survival (d; Kaplan-Meier analysis and Log-Rank test). **e,f**. The fourth set of therapeutic experiment in LAPC9 cells. Shown are representative lung images (e; animal number and tumor weight indicated on top; scale bar, 100 μm) and quantification of lung metastases (f; mean ± S.D, *n* = 10/group).](nihms255508f2){#F2}

![miR-34a inhibits clonal and clonogenic properties of PCa cells\
**a**. Holoclone assays in Du145 cells. Cells transfected with miR-NC (NC) or miR-34a (34a) oligos were used in three experiments (Exp. I, 100 cells/well scored on d 9; Exp. II, 100 cells/well scored on d 13; Exp. III, 500 cells/well scored on d 7). **b**. Clonogenic assays in Du145 cells. Cells (3,000/well) were plated in MG and colonies counted on day 13. NT, non-transfected. **c**. MG clonogenic assays in LAPC4 cells. Two experiments were performed (Exp. I, 1,250 cells/well scored on d 5, \**P* = 0.005; Exp. II, 25,000 cells/well scored on d 5, \*\**P* = 0.015). **d**. Sphere assays in LAPC4 cells. LAPC4 cells infected with lenti-ctl (C) or lenti-34a were plated (10,000 cells/well) for both 1° and 2° assays and spheres scored on d 15. **e**. Holoclone assays in PPC-1 cells. Cells transfected with miR-NC or miR-34a oligos were plated (500 cells/well) in triplicate and holoclones quantified on d 5. **f**. Sphere assays in HPCa101 (Gleason 9) cells. Purified HPCa101 cells infected with lenti-ctl (C) or lenti-34a were plated (20,000 cells/well) for both 1° and 2° and spheres scored 3 weeks later. **g,h**. Sphere assays in purified CD44^+^ HPCa116 (Gleason 7) cells transfected with NC or miR-34a oligos (g) or CD44^−^ HPCa116 cells transfected with anti-NC or anti-34a oligos (h). Spheres were scored on d 15.](nihms255508f3){#F3}

![CD44 as a direct and functional target of miR-34a\
**a**. Representative CD44 IHC images in Du145 tumors from cells infected with MSCV-PIG (control) or MSCV-34a vectors (Western blot on the right) and PC3 tumors harvested from animals treated with miR-NC or miR-34a oligos. Scale bars, 10 μm. **b**. miR-34a downregulates CD44 in Du145 (left) and PPC-1 (right) cells. Relative levels of CD44 indicated at the bottom. **c**. Schematic of two putative miR-34a binding sites in the CD44 3'-UTR. **d**. Luciferase experiments in Du145 cells (\**P* \<0.01). **e**. CD44 knockdown inhibits LAPC4 tumor regeneration (see [Supplementary Fig. 12](#SD1){ref-type="supplementary-material"}). **f**,**g**. CD44 knockdown inhibits PC3 cell metastasis evidenced by both quantification (f) and images (g; scale bar, 100 μm). **h,i**. Invasion assays. miR-34a oligos inhibit Matrigel invasion of CD44^+^ Du145 cells (h), which was partially overcome by overexpression of a human CD44 cDNA lacking the miR-34a binding sites at the 3'-UTR (i). Invasion was expressed as values relative to the corresponding controls. **j**. A schematic summary. The part highlighted in red refers to the novel findings made in the present study.](nihms255508f4){#F4}
